MRNS - Marinus Pharmaceuticals Inc. (MRNS) Q4 2023 Earnings Call Transcript

2024-03-05 21:29:12 ET

Start Time: 16:30

End Time: 17:36

Marinus Pharmaceuticals, Inc. (MRNS)

Q4 2023 Earnings Conference Call

March 05, 2024, 16:30 PM ET

Company Participants

Scott Braunstein - CEO and Chairman

Christy Shafer - Chief Commercial Officer

Joseph Hulihan - Chief Medical Officer

Steven Pfanstiel - CFO and COO

Sonya Weigle - SVP, IR, Human Resources and Corporate Affairs

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Peyton Bohnsack - TD Cowen

Andrew Tsai - Jefferies

Charles Duncan - Cantor Fitzgerald

Joon Lee - Truist Securities

Basma Radwan - Leerink Partners

Douglas Tsao - HC Wainwright

Jason Butler - Citizens JMP

Brian Skorney - Baird

Presentation

Operator

Ladies and gentlemen, greetings and welcome to Marinus Pharmaceuticals' Fourth Quarter and Full Year 2023 Financial Results and Business Update Call. Today's call is being recorded and all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.

And it is my pleasure to introduce your host, Sonya Weigle, Senior Vice President of Investor Relations, Human Resources and Corporate Affairs. Ms. Weigle, you may begin.

Sonya Weigle

Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.

I will now turn the call over to our CEO, Dr. Scott Braunstein.

Scott Braunstein

Thank you, Sonya. Marinus concluded 2023 with a strong finish across all fronts; commercial, clinical and operational. On today's call, I'll provide a brief overview of some of the key areas before turning it over to our leadership team. ...

For further details see: